Global Gastrointestinal Stromal Tumour Treatment Market Report and Forecast 2024-2032

Global Gastrointestinal Stromal Tumour Treatment Market Outlook

The global gastrointestinal stromal tumour treatment market is expected to grow at a CAGR of 5.8% in the forecast period of 2024-2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Growing Awareness Regarding the Disease to Aid the Market Growth of Gastrointestinal Stromal Tumour Treatment

The market growth of gastrointestinal stromal tumour treatment is being aided by the growing prevalence of the disease across the globe. The market is propelled by the growing awareness and understanding of this tumour, which has catapulted the market growth tremendously. Further, the ongoing R&D activities across several medical research institutes and organizations worldwide are encouraging the industry growth of gastrointestinal stromal tumour.

Region-wise, North America is a significant market for gastrointestinal stromal tumour treatment and is expected to maintain its significance over the forecast period as well. The healthy market growth in this region could be attributed to the growing adoption of unhealthy dietary options and the consequent bad lifestyles of people, accelerated by the usage of food additives in such food products. Also, the rising prevalence of genetic disorders is a fundamental factor contributing to the speedy growth of this industry in North America in the upcoming years. In addition to this, Europe and the Asia Pacific are expected to observe healthy growth in the forecast period.

Gastrointestinal Stromal Tumour Treatment: Market Segmentation

Gastrointestinal stromal tumours (GISTs) are referred to as soft tissue sarcomas, which can be situated in any part of the digestive system. They are generally found in the stomach and small intestine. GISTs begin to form in specialized nerve cells found in the walls of the digestive system.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

On the basis of treatment type, the market is divided into:

• Targeted Drug Therapy
• Chemotherapy
• Radiation Therapy
• Surgery
• Others

Based on indication, the industry can be segmented into:

• Stomach
• Small Intestine
• Others

By end use, the industry is categorised into:

• Hospitals
• Cancer Treatment Centres
• Clinics
• Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Growing Focus on Technological Developments to Aid the Market Growth of Gastrointestinal Stromal Tumour Treatment

The gastrointestinal stromal tumour treatment industry is being driven by the developments in clinical practice guidelines. Further, the robust growth of the healthcare sector and the growing focus on technological developments in this industry is expected to fuel the market growth of gastrointestinal stromal tumour treatment in the forecast period. Furthermore, the growing investments in the medical sector, particularly in emerging economies, are expected to provide lucrative opportunities in the forecast period. All the aforementioned factors are expected to bolster the market growth in the coming years.

Key Industry Players in the Global Gastrointestinal Stromal Tumour Treatment Market

The report gives a detailed analysis of the following key players in the global gastrointestinal stromal tumour treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Pfizer Inc.  
• Novartis AG
• Bayer AG
• Blueprint Medicines Corporation
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report